Abstract
PURPOSE: We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers. PATIENTS AND METHODS: Noncastrate patients with 150 ng/dL) and an undetectable prostate-specific antigen (PSA;